Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802880 · ClinicalTrials.gov registry record · Phase 2
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00802880 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 80 participants.
The verdict
NCT00802880, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.
Interventions
- DRUG Dacarbazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00802880
The ClinicalTrials.gov registry entry for NCT00802880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dacarbazine is the first listed.
NCT00802880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00802880 about?
NCT00802880 is a clinical study titled "Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma". The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.
What is the current status of trial NCT00802880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2009-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT00802880?
The interventions under investigation include: Dacarbazine (DRUG).
Who is sponsoring clinical trial NCT00802880?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.